SAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time (ET)/6:00 a.m. Pacific Time (PT) on Tuesday, September 27, 2016. A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website at http://www.nektar.com. A webcast replay of the conference call will be available through Friday, October 14, 2016.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 86947111 (Nektar Therapeutics is the host)
Nektar Therapeuticshas a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology,Nektaris developing NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain,Nektarhas an exclusive worldwide license agreement with AstraZeneca for MOVANTIK (naloxegol), the firstFDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in theEuropean Unionas MOVENTIG (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia,Nektarhas a collaboration agreement with Baxalta for ADYNOVATE [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in theU.S.andJapanfor patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations withBayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.
Nektar'stechnology has enabled nine approved products in theU.S.orEuropethrough partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, Baxalta's ADYNOVATE, UCB's Cimzia for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS for hepatitis C and Amgen's Neulasta for neutropenia.
Nektaris headquartered inSan Francisco, California, with additional operations inHuntsville, AlabamaandHyderabad, India. Further information about the company and its drug development programs and capabilities may be found online athttp://www.nektar.com.
MOVANTIK is a trademark and MOVENTIG is a registered trademark of the AstraZeneca group of companies. ADYNOVATE is a trademark of Baxalta Inc.
ONZEALD is a trademark ofNektar Therapeutics.
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-investor--analyst-conference-call-to-discuss-new-clinical-collaboration-with-bristol-myers-squibb-300334703.html
SOURCE Nektar Therapeutics